[
  {
    "ts": null,
    "headline": "ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data",
    "summary": "ORIC's ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. Read why I am neutral on ORIC stock.",
    "url": "https://finnhub.io/api/news?id=b8adc832885d57ebc67b473c3828e685bd6413a80d2eedee4116d146c10d33b7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738472729,
      "headline": "ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data",
      "id": 132514154,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "ORIC's ORIC-533 was promising but failed in trials, leaving ORIC-114 and ORIC-944 as key pipeline assets. Read why I am neutral on ORIC stock.",
      "url": "https://finnhub.io/api/news?id=b8adc832885d57ebc67b473c3828e685bd6413a80d2eedee4116d146c10d33b7"
    }
  }
]